Alessandro Furlan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/719070/publications.pdf

Version: 2024-02-01

23 papers

760 citations

759233 12 h-index 27 g-index

28 all docs 28 docs citations

28 times ranked

1311 citing authors

#	Article	IF	CITATIONS
1	An Overview of the Circadian Clock in the Frame of Chronotherapy: From Bench to Bedside. Pharmaceutics, 2022, 14, 1424.	4.5	4
2	Evofosfamide Is Effective against Pediatric Aggressive Glioma Cell Lines in Hypoxic Conditions and Potentiates the Effect of Cytotoxic Chemotherapy and Ionizing Radiations. Cancers, 2021, 13, 1804.	3.7	5
3	Hypoxia in Solid Tumors: How Low Oxygenation Impacts the "Six Rs―of Radiotherapy. Frontiers in Endocrinology, 2021, 12, 742215.	3.5	38
4	H3.3K27M Mutation Controls Cell Growth and Resistance to Therapies in Pediatric Glioma Cell Lines. Cancers, 2021, 13, 5551.	3.7	10
5	Large-Scale Virtual Screening Against the MET Kinase Domain Identifies a New Putative Inhibitor Type. Molecules, 2020, 25, 938.	3.8	7
6	Control of cell death/survival balance by the MET dependence receptor. ELife, 2020, 9, .	6.0	10
7	Ets-1 drives breast cancer cell angiogenic potential and interactions between breast cancer and endothelial cells. International Journal of Oncology, 2019, 54, 29-40.	3.3	25
8	Mathematical models converge on PGC1 $\hat{l}\pm$ as the key metabolic integrator of SIRT1 and AMPK regulation of the circadian clock. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 13171-13172.	7.1	7
9	HEXIM1 Diffusion in the Nucleus Is Regulated by Its Interactions with Both 7SK and P-TEFb. Biophysical Journal, 2019, 117, 1615-1625.	0.5	7
10	FRET Image Correlation Spectroscopy Reveals RNAPII-Independent P-TEFb Recruitment on Chromatin. Biophysical Journal, 2018, 114, 522-533.	0.5	10
11	Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers. Journal of the National Cancer Institute, 2017, 109, .	6.3	83
12	Caspases shutdown nonsense-mediated mRNA decay during apoptosis. Cell Death and Differentiation, 2015, 22, 1754-1763.	11,2	41
13	Necrosis- and apoptosis-related Met cleavages have divergent functional consequences. Cell Death and Disease, 2015, 6, e1769-e1769.	6.3	12
14	How does met regulate the survival/apoptosis balance?. Hepatology, 2014, 60, 1108-1109.	7.3	2
15	Thirty Years of Research on Met Receptor to Move a Biomarker from Bench to Bedside. Cancer Research, 2014, 74, 6737-6744.	0.9	64
16	Etsâ€1 controls breast cancer cell balance between invasion and growth. International Journal of Cancer, 2014, 135, 2317-2328.	5.1	29
17	Met acts through Abl to regulate p53 transcriptional outcomes and cell survival in the developing liver. Journal of Hepatology, 2012, 57, 1292-1298.	3.7	17
18	â€~Click' synthesis of a triazole-based inhibitor of Met functions in cancer cells. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4693-4696.	2.2	34

ALESSANDRO FURLAN

#	Article	IF	CITATION
19	Combined Drug Action of 2-Phenylimidazo[2,1-b]Benzothiazole Derivatives on Cancer Cells According to Their Oncogenic Molecular Signatures. PLoS ONE, 2012, 7, e46738.	2.5	8
20	Identification of new aminoacid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling. European Journal of Medicinal Chemistry, 2012, 47, 239-254.	5.5	70
21	Abl interconnects oncogenic Met and p53 core pathways in cancer cells. Cell Death and Differentiation, 2011, 18, 1608-1616.	11.2	57
22	Etsâ€1 triggers and orchestrates the malignant phenotype of mammary cancer cells within their matrix environment. Journal of Cellular Physiology, 2008, 215, 782-793.	4.1	32
23	ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Glycobiology, 2006, 16, 54-64.	2.5	173